ProQR Therapeutics NV (PRQR) Research Coverage Started at Janney Montgomery Scott
Equities research analysts at Janney Montgomery Scott initiated coverage on shares of ProQR Therapeutics NV (NASDAQ:PRQR) in a report issued on Wednesday. The firm set a “neutral” rating on the biopharmaceutical company’s stock.
Several other research firms also recently commented on PRQR. Chardan Capital initiated coverage on ProQR Therapeutics NV in a report on Monday, June 20th. They issued a “neutral” rating and a $4.50 price objective on the stock. Leerink Swann reiterated a “buy” rating on shares of ProQR Therapeutics NV in a report on Thursday, August 18th. Zacks Investment Research downgraded ProQR Therapeutics NV from a “hold” rating to a “sell” rating in a report on Saturday, August 20th. Finally, JMP Securities reiterated a “buy” rating on shares of ProQR Therapeutics NV in a report on Tuesday, September 6th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $15.94.
ProQR Therapeutics NV (NASDAQ:PRQR) traded down 3.69% on Wednesday, reaching $7.30. The company had a trading volume of 58,525 shares. The company’s 50 day moving average is $5.87 and its 200-day moving average is $5.19. ProQR Therapeutics NV has a one year low of $3.48 and a one year high of $16.23. The firm’s market capitalization is $170.43 million.
ProQR Therapeutics NV (NASDAQ:PRQR) last released its quarterly earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.00. On average, equities research analysts expect that ProQR Therapeutics NV will post ($2.14) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in ProQR Therapeutics NV stock. Redmile Group LLC boosted its stake in shares of ProQR Therapeutics NV (NASDAQ:PRQR) by 5.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 581,638 shares of the biopharmaceutical company’s stock after buying an additional 28,925 shares during the period. Redmile Group LLC owned about 2.49% of ProQR Therapeutics NV worth $2,815,000 as of its most recent filing with the SEC. Institutional investors own 39.21% of the company’s stock.
About ProQR Therapeutics NV
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
Receive News & Stock Ratings for ProQR Therapeutics NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics NV and related stocks with our FREE daily email newsletter.